Growth of kidney-transplanted pediatric patients treated with sirolimus

Experimental findings indicate that sirolimus (SRL) inhibits longitudinal growth by mechanisms potentially related to its inhibitory effects on both cell proliferation and expression of vascular endothelial growth factor (VEGF). The aim of this study was to investigate the growth pattern of kidney-t...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric nephrology (Berlin, West) West), 2011-06, Vol.26 (6), p.961-966
Main Authors: González, David, García, Clotilde D., Azócar, Marta, Waller, Simon, Alonso, Angel, Ariceta, Gema, Mejía, Natalia, Santos, Fernando
Format: Article
Language:English
Subjects:
Age
Cell growth
Child
Children
Corticosteroids
Drug therapy
Female
Gender
Graft Rejection - immunology
Graft Rejection - prevention & control
Growth
Growth disorders
Growth Disorders - chemically induced
Growth Disorders - pathology
Growth hormones
Health aspects
Humans
Immunosuppressive Agents - therapeutic use
Kidney Transplantation - immunology
Kidney transplants
Kidneys
Male
Medicine & Public Health
Nephrology
Organ transplant recipients
Original Article
Pediatric research
Pediatrics
Rapamycin
Renal Insufficiency - immunology
Renal Insufficiency - surgery
Retrospective Studies
Risk factors
Sirolimus - therapeutic use
Steroids
Transplantation
Transplantation, Homologous
Urology
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Experimental findings indicate that sirolimus (SRL) inhibits longitudinal growth by mechanisms potentially related to its inhibitory effects on both cell proliferation and expression of vascular endothelial growth factor (VEGF). The aim of this study was to investigate the growth pattern of kidney-transplanted children treated with SRL in a multicenter observational clinical study. Height, change in height SD (Δ height) and growth velocity of pediatric patients with renal transplant were calculated at 0, 6, 12, and 24 months after starting SRL. Controls of kidney-transplanted children not treated with SRL were matched by age, gender, renal function, and dose of corticosteroids. Sixty-eight children (34 SRL, 34 controls) were enrolled in the study. Nephrotoxicity was the most frequent indication to start therapy with SRL. SRL exerted an adverse effect on growth as demonstrated by significantly lower ( p  
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-011-1811-3